Mr. Speaker, the announcement yesterday and the legislation that is before the House has the same stringent standards for licensing of drug products as was there before and, in fact, we have expanded it by allowing the minister the opportunity to attach conditions post-market to those products as well.
This is what the life cycle approach is all about. It will be additional health and safety for Canadians. That is why we encourage members to back this legislation.